HOPKINTON, Mass.—Caliper Life Sciences recently announced the formation of a services division called Caliper Discovery Alliances and Services (CDAS), which the company believes will help pharmaceutical clients cross the "In Vitro-In Vivo Bridge". Key to the launch was the acquisitions in the last 15 months of NovaScreen Biosciences and Xenogen Biosciences.
"The demand for outsourced drug discovery services is growing rapidly as companies increasingly recognize the critical need for comprehensive characterization of potential safety or side effect liabilities of their drug candidates," said David Manyak, Caliper Life Sciences EVP of discovery services and head of CDAS. According to recent research by Frost & Sullivan, the CRO market in Europe alone is expected to more than double from $4.8 billion in 2005 to $10.2 billion by 2010.
CDAS will offer more than 700 in vitro screens for systems such as GPCRs, kinases, and ion channels, as well as ADMET panels. The company will also offer more than 85 in vivo pharmacological screens, as well as animal models of various therapeutic areas.
